First IVD Product Sale in Switzerland


Sienna is pleased to announce the first sale of the company’s hTERT test in Switzerland through its distribution partner, Biosystems Switzerland AG.

Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna’s novel IVD test, the first order by a Swiss laboratory has been delivered. This follows the training of Biosystems key personnel by Sienna in late 2017, and evaluation and clinical validation by the customer.

Biosystems Switzerland CEO, Urs Brunner said: “Interest in the hTERT test has been very encouraging. Although urine cytology is non-invasive it has significant limitations in terms of sensitivity, particularly when it comes to low-grade or early-stage bladder cancer. Having a biomarker test that can provide additional clinically significant information for the diagnosing physician, while using the same urine sample collected for cytology, adds real value to the diagnostic process, and pathologists appreciate this.”

Sienna is encouraged by the interest shown in the hTERT test in Switzerland: “The team at Biosystems Switzerland has done a great job of generating a pipeline of interested laboratories, several of which are well advanced in evaluating the test for clinical use. This is a key milestone in our ongoing geographical expansion strategy,” said Minesh Lalla, Business Development Manager, Sienna Cancer Diagnostics.


No Very

Captcha Image

Sign up for updates